Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Biotherapy Centre, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Future Oncol. 2022 Sep;18(30):3449-3461. doi: 10.2217/fon-2021-1549. Epub 2022 Oct 10.
Liposarcoma (LPS) is a rare adipocyte-derived malignancy accounting for 20% of all soft tissue sarcomas. Although surgery and chemotherapy are the standard treatment for LPS, the large tumor burden and high recurrence rate make it difficult to treat, especially when the disease progresses. With the progress of immunotherapies in other tumors such as melanoma and lung cancer, interest has been risen in exploring immunotherapy for LPS. This review discusses the understanding of the tumor microenvironment of LPS; the current status of immunotherapy in LPS, including immune checkpoint inhibitors, adoptive cell therapy, cancer vaccines, oncolytic viruses and combination therapies; and the future directions for exploiting strategies to make the effect of immunotherapy stronger and more durable.
脂肪肉瘤（LPS）是一种罕见的脂肪细胞来源的恶性肿瘤，占所有软组织肉瘤的 20%。尽管手术和化疗是 LPS 的标准治疗方法，但由于肿瘤负荷大、复发率高，治疗起来很困难，尤其是在疾病进展时。随着免疫疗法在黑色素瘤和肺癌等其他肿瘤中的进展，人们对 LPS 的免疫疗法产生了兴趣。这篇综述讨论了 LPS 肿瘤微环境的认识；LPS 中免疫疗法的现状，包括免疫检查点抑制剂、过继细胞疗法、癌症疫苗、溶瘤病毒和联合疗法；以及探索使免疫疗法效果更强、更持久的策略的未来方向。
